MedPath

SMAD2, SMAD3 AND TGF-β GENE EXPRESSION IN URGE URINARY INCONTINENCE

Completed
Conditions
SMAD3
Pelvic Organ Prolapse
SMAD2
TGF-β
Urge Urinary Incontinence
Interventions
Genetic: SMAD2
Registration Number
NCT04525105
Lead Sponsor
Muğla Sıtkı Koçman University
Brief Summary

Urge urinary incontinence (UUI) is a common health problem. Changes in collagen metabolism in pelvic support organs, such as uterosacral ligaments (USLs), might be responsible for the complex pathophysiology of UUI. The TGF-β pathway is involved in collagen synthesis and degradation. The Transforming Growth Family- β (TGF-β) superfamily has essential intracellular signaling components, such as newly identified SMAD family members. We evaluated the changes in the levels of TGF-β and SMAD gene and protein expression in the USL of patients with concomitant pelvic organ prolapse (POP) and UUI.

Detailed Description

This study included 10 patients who had been diagnosed with POP and UUI in the study group and 14 asymptomatic women without complaints of POP and UUI in the control group. Biopsy samples were collected from bilateral USL tissues during vaginal or abdominal hysterectomy. Total RNA was extracted from USL tissue and analyzed by qPCR. The protein expression levels were also analyzed with ELISA.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
24
Inclusion Criteria
  • patients who had been diagnosed with POP and UUI
  • asymptomatic women without complaints of POP and UUI
Exclusion Criteria
  • Women who have SUI,
  • a history of gynecologic malignancy,
  • endometriosis,
  • connective tissue disorders,
  • asthma,
  • previous pelvic inflammatory disease,
  • pelvic radiation anamnesis,
  • smoking,
  • previous surgery for POP or UI,
  • those on steroid therapy and hormone replacement therapy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Study groupSMAD2wıth URGE INCONTINANCE
Control groupSMAD2not urge incontinance
Primary Outcome Measures
NameTimeMethod
SMAD3intraoperative

tissue expression and protein level

TGF-ß1 mRNA Expression Levelsintraoperative

tissue expression and protein level

SMAD2intraoperative

tissue expression and protein level

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Mugla Sıtkı Kocman University Faculty of Medicine

🇹🇷

Mugla, Turkey

© Copyright 2025. All Rights Reserved by MedPath